## ULTA: Ulta Beauty, Inc. - XLY: Consumer Cyclical

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 5.3% in mid entry zone (3.0-6.0%), top 10% cross-sectional ranking. Short-term MRS_5 (2.9%) confirms momentum alignment. Strong momentum (+4.5% 5-day acceleration). Outperforming sector by 6.1%. Caution: overbought RSI (77).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($624.90)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Robeco Institutional Asset Management B.V. Raises Stake in Ulta Beauty Inc. $ULTA**
- Source: MarketBeat | 20260107T111031 | Somewhat-Bullish | Relevance: 100%
- Robeco Institutional Asset Management B.V. significantly boosted its stake in Ulta Beauty Inc. during the third quarter, increasing its holdings by 137.3% to own 212,952 shares valued at approximately $116.4 million. This increased stake comes as Ulta Beauty exceeded quarterly expectations, with strong EPS and revenue, leading to raised FY2025 guidance and multiple analyst price target increases. Despite a "Moderate Buy" rating, some market commentary suggests Ulta's recent rally might be overextended based on valuation metrics.

**2. Ulta Beauty (ULTA) Valuation Check As Rare Beauty Rollout And Philanthropy Ignite Investor Interest**
- Source: Simply Wall Street | 20260106T202315 | Somewhat-Bullish | Relevance: 100%
- Ulta Beauty (ULTA) is facing a valuation check despite strong recent share price performance and the upcoming rollout of Selena Gomezâ€™s Rare Beauty line, coupled with mental health initiatives. The company's stock is trading near an all-time high and slightly above analyst price targets, prompting questions about remaining upside for investors. While expansion plans aim to attract Gen Z and Millennials and boost margins, potential pressure points like higher costs and the loss of Target shop-in-shop revenue after 2026 could affect future performance.

**3. Is Ulta Beauty Inc Experiencing a Bullish or Bearish Trend in the Market?**
- Source: Bitget | 20260106T201500 | Bullish | Relevance: 100%
- Ulta Beauty Inc (NYSE: ULTA) has seen its short interest decrease by 8.82% to 2.10 million shares, representing 6.2% of its available shares. This decline in short interest suggests growing optimism among investors, as it indicates fewer shares are being bet against. Compared to its peers, Ulta Beauty Inc has a lower short interest, further implying a potentially bullish sentiment for the stock.

**4. Beauty and Cosmetics Retailer Stocks Q3 Earnings: Ulta (NASDAQ:ULTA) Best of the Bunch**
- Source: Finviz | 20260106T201144 | Bullish | Relevance: 100%
- Ulta (NASDAQ:ULTA) was the top performer among beauty and cosmetics retailers in the Q3 earnings season, exceeding analyst expectations for revenue and EBITDA. Other retailers like Sally Beauty (NYSE:SBH) also had strong quarters, while Bath and Body Works (NYSE:BBWI) and Warby Parker (NYSE:WRBY) showed mixed results despite some challenges. Overall, the sector saw positive share price performance after earnings.

**5. Is Ulta Beauty Inc Experiencing a Bullish or Bearish Trend in the Market?**
- Source: Bitget | 20260106T042215 | Somewhat-Bullish | Relevance: 100%
- Short interest in Ulta Beauty Inc (NYSE: ULTA) has decreased by 8.82%, with 2.10 million shares sold short, representing 6.2% of its float. This lower short interest compared to its peer group (average 14.47%) suggests a potentially more optimistic market sentiment for Ulta Beauty. While a drop in short interest doesn't guarantee a price increase, it indicates fewer investors are betting against the stock.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-07 | UBS | $780 | $690 | +13% |
| 2026-01-02 | Argus Research | $700 | $650 | +8% |
| 2025-12-10 | Oppenheimer | $675 | $615 | +10% |
| 2025-12-08 | Morgan Stanley | $640 | $600 | +7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-07 | UBS | main | Buy |
| 2026-01-02 | Argus Research | main | Buy |
| 2025-12-10 | Oppenheimer | main | Outperform |
| 2025-12-08 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 1 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+0.6%)
- Blackrock Inc.: 9.0% (-2.1%)
- JPMORGAN CHASE & CO: 5.5% (+99.0%)
- State Street Corpora: 4.4% (+2.3%)
- Sanders Capital, LLC: 2.8% (+8.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 5 raises (avg +12%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +4.5% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 2.44 elevated, pricing in significant growth expectations. Forward P/E 23.2x stretched relative to 11% growth. Quality metrics strong (ROE 48%, ROA 15%). Analyst sentiment positive (5 raises, avg +12%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $29.4B |
| Beta | 0.85 |
| 52W Range | $309.01 - $658.20 |
| Short Interest | 6.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.44 |
| Forward P/E | 23.2 |
| Current P/E | 25.7 |
| YoY Growth | 10.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 0.8% to 5.3% (+4.5% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (3.0-6.0%), cross-sectional ranking at 90th percentile. MRS_5 at 2.9% confirms short-term momentum alignment. Outperforming sector by 6.1pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (3.02), confirming momentum. RSI overbought at 77, risk of mean reversion. OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 5.29% (CS: 90) | Strong |
| RSI_14 | 76.6 | Overbought |
| MACD Histogram | 3.02 | Bullish |
| vs SMA20 | 1.078x | Above |
| vs SMA50 | 1.172x | Above |
| vs SMA200 | 1.332x | Above |

### Decision

- **Verdict:** BUY
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $655.36
- **Stop Loss:** $624.90 (4.6% risk)
- **Target:** $701.05 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 16
- **Position Value:** $10,485.76
- **Portfolio %:** 10.49%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX at 15.38 sits in the normal range (18th percentile of 52-week) with modest upward drift, while yield curve remains positively sloped (+62bps 10Y-3M) supporting risk assets. Breadth at 59.5% shows healthy participation, though elevated put/call ratio (1.12) suggests some hedging activity. FOMC 20 days out provides runway for current conditions to persist.*

### Earnings

**Next:** 2026-03-12 (Est: $7.15)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $4.60 | $5.14 | +11.7% |
| 2025Q3 | $5.04 | $5.78 | +14.6% |
| 2025Q2 | $5.80 | $6.70 | +15.5% |
| 2025Q1 | $7.15 | $8.46 | +18.4% |

---
*RULE-based L3 | 2026-01-08 08:02 | MRS_10*